Royal Caribbean Cruises Has Upside To Estimates, Says Bullish Analyst
Analyst initiates coverage of Royal Caribbean Cruises with Buy rating and price target of $164.
Discover Financial Gears Up For Q1 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Discover Financial Services (NYSE: DFS) is expected to release earnings results for its first quarter, after the closing bell on April 17, 2024.
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Wall Street’s Most Accurate Analysts’ Views On 3 Real Estate Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
These Analysts Cut Their Forecasts On J.B. Hunt Following Downbeat Earnings
J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT) reported downbeat first-quarter 2024 results on Tuesday.
Travelers Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts
The Travelers Companies, Inc. (NYSE: TRV) is set to release earnings results for its first quarter before the opening bell on April 17, 2024.
Analysts Question Commercial Viability of Marinus’ IV Ganaxolone After Interim Analysis Miss
Marinus Pharmaceuticals' phase 3 RAISE trial on IV ganaxolone for refractory status epilepticus fails interim analysis. Future development to be assessed post final results review.
Netflix Q1 Earnings Preview: Subscriber Growth, Potential Price Increase, Ad-Tier Plan And More On What Wall Street Expects
Netflix stock is in the spotlight for the week with imminent first quarter financial results. Analysts are looking at subscriber adds and a potential price increase as the key headline items.
Marvell Analyst Tags Stock as Top Pick for AI Boom, Predicts Significant Industry Upswing
Analyst initiates coverage on MRVL with Outperform rating and $88 price target, citing strong outlook for semiconductor sector and Marvell's potential in networking and AI. MRVL stock up 68% in 12 months.
Avalo Therapeutics’ Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.